Tissue Regenix Group (LSE:TRX) Debt-to-Equity : 0.31 (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Tissue Regenix Group Debt-to-Equity?

Tissue Regenix Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.51 Mil. Tissue Regenix Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £6.92 Mil. Tissue Regenix Group's Total Stockholders Equity for the quarter that ended in Dec. 2023 was £23.82 Mil. Tissue Regenix Group's debt to equity for the quarter that ended in Dec. 2023 was 0.31.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Tissue Regenix Group's Debt-to-Equity or its related term are showing as below:

LSE:TRX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09 Med: 0.23 Max: 0.31
Current: 0.31

During the past 13 years, the highest Debt-to-Equity Ratio of Tissue Regenix Group was 0.31. The lowest was 0.09. And the median was 0.23.

LSE:TRX's Debt-to-Equity is ranked worse than
65.56% of 1080 companies
in the Biotechnology industry
Industry Median: 0.145 vs LSE:TRX: 0.31

Tissue Regenix Group Debt-to-Equity Historical Data

The historical data trend for Tissue Regenix Group's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tissue Regenix Group Debt-to-Equity Chart

Tissue Regenix Group Annual Data

Trend

Jan14

Jan15

Jan16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.09

0.19

0.23

0.31

Tissue Regenix Group Semi-Annual Data
	Jan14	Jul14	Jan15	Jul15	Jan16	Jul16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.23	0.27	0.31	0.31	0.31

Competitive Comparison of Tissue Regenix Group's Debt-to-Equity

For the Biotechnology subindustry, Tissue Regenix Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tissue Regenix Group's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Tissue Regenix Group's Debt-to-Equity falls into.

Tissue Regenix Group Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Tissue Regenix Group's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.507	+	6.915)	/	23.819
	=	0.31

Tissue Regenix Group's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.507	+	6.915)	/	23.819
	=	0.31

Tissue Regenix Group (LSE:TRX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Tissue Regenix Group Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Tissue Regenix Group's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Tissue Regenix Group (LSE:TRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tissue Regenix Group PLC (LSE:TRX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

LSW:Germany

Address

Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY

Website

https://www.tissueregenix.com

Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.